Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 90.60B +37.3% |
| Revenue (ttm) | 16.90B +18.6% |
| Net Income | 4.82B +5.2% |
| EPS | 45.17 +8.6% |
| Shares Out | 100.35M |
| PE Ratio | 19.99 |
| Forward PE | 11.23 |
| Dividend | $3.76 (0.42%) |
| Ex-Dividend Date | Nov 20, 2026 |
| Volume | 1,407,352 |
| Open | 938.51 |
| Previous Close | 930.67 |
| Day's Range | 901.53 - 948.11 |
| 52-Week Range | 591.52 - 991.73 |
| Beta | 0.10 |
| Analysts | Buy |
| Price Target | 977.93 (+8.31%) |
| Earnings Date | Oct 30, 2026 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $977.93, which is an increase of 8.31% from the latest price.
News
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in Londo...
Regeneron price target raised to $913 from $810 at RBC Capital
RBC Capital raised the firm’s price target on Regeneron (REGN) to $913 from $810 and keeps a Sector Perform rating on the shares. The company’s strong commercial quarter underscores the…
Regeneron price target raised to $997 from $835 at Leerink
Leerink analyst David Risinger raised the firm’s price target on Regeneron (REGN) to $997 from $835 and keeps a Market Perform rating on the shares following significant Q3 results upside.
Regeneron price target raised to $982 from $780 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Regeneron (REGN) to $982 from $780 and keeps a Buy rating on the shares. The company posted strong top- and…
Regeneron price target raised to $980 from $795 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Regeneron (REGN) to $980 from $795 and keeps an Overweight rating on the shares. The firm sees “something closer to ~$80/share” in…
Regeneron price target raised to $1,100 from $1,030 at Guggenheim
Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,100 from $1,030 and keeps a Buy rating on the shares.
Regeneron price target raised to $1,175 from $922 at Canaccord
Canaccord raised the firm’s price target on Regeneron (REGN) to $1,175 from $922 and keeps a Buy rating on the shares. The firm said Dupixent’s impressive beat vs consensus reaffirms…
Regeneron price target raised to $875 from $761 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Regeneron (REGN) to $875 from $761 and keeps a Neutral rating on the shares. The firm updated its model following…
Regeneron price target raised to $812 from $756 at Bernstein
Bernstein raised the firm’s price target on Regeneron (REGN) to $812 from $756 and keeps a Market Perform rating on the shares. The firm notes Regeneron delivered a strong Q3…
Regeneron price target raised to $925 from $750 at Wells Fargo
Wells Fargo raised the firm’s price target on Regeneron (REGN) to $925 from $750 and keeps an Equal Weight rating on the shares. The firm cites the company’s strong commercial…
Regeneron price target raised to $1,030 from $908 at BofA
BofA raised the firm’s price target on Regeneron (REGN) to $1,030 from $908 and keeps a Buy rating on the shares. The company reported solid Q3 results across key products,…
Regeneron price target raised to $855 from $779 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $855 from $779 and keeps an Equal Weight rating on the shares. The firm views the…
Regeneron price target raised to $1,000 from $865 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Regeneron (REGN) to $1,000 from $865 and keeps an Overweight rating on the shares.
Regeneron price target raised to $1,050 from $950 at JPMorgan
JPMorgan raised the firm’s price target on Regeneron (REGN) to $1,050 from $950 and keeps an Overweight rating on the shares after the company reported a meaningful Q3 beat, driven…
Regeneron price target raised to $1,020 from $911 at Raymond James
Raymond James raised the firm’s price target on Regeneron (REGN) to $1,020 from $911 and keeps an Outperform rating on the shares. The firm raised its price target following a…
Regeneron price target raised to $825 from $740 at Citi
Citi raised the firm’s price target on Regeneron (REGN) to $825 from $740 and keeps a Neutral rating on the shares. The firm upped Regeneron’s estimates post the better than…
Regeneron Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 36% and non-GAAP EPS 70%, with record sales for DUPIXENT, EYLEA HD, and LIBTAYO. Investment in a broad pipeline is set to accelerate, while 2027 R&D expense is expected to rise at a mid-teens rate.
Regeneron Pharmaceuticals Earnings release: Q3 2026
Regeneron Pharmaceuticals released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q3 2026
Regeneron Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 30, 2026.
Regeneron Pharmaceuticals Slides: Q3 2026
Regeneron Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
Regeneron Reports Third Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.
Regeneron extends US agreement for additional supply of Ebola treatment
Regeneron said on Monday it extended its agreement with a US health authority to provide additional supply of its Ebola treatment, amid a growing outbreak in Africa.
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placeb...